Biopharmaceutical products company Sinovac Biotech Ltd (NASDAQ:SVA) announced on Friday that it recorded a net income attributable to common shareholders of USD6.3m (USD0.06 per basic and diluted share) for the third quarter ended 30 September 2019.
This reflects a decline in earnings when compared with net income attributable to common shareholders of USD8.9m ( USD0.12 per basic and diluted share) in the prior year period
Sales of USD64.3m were recorded for the third quarter of 2019, a rise of 19.3% from sales of USD53.9m in the prior year period, due to higher sales of influenza vaccines.
R&D expenses of USD5.7m were recorded in the third quarter of 2019, an increase versus R&D of USD4.7m in the prior year period, as the company continued to invest in the development of its pipeline of product candidates, including sIPV, PPV and the varicella vaccine.
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access